Doxotor 50 mg (Doxorubicin) Injection

Introduction to Doxotor 50 mg (Doxorubicin) Injection

Doxotor 50 mg, manufactured by Eskayef Pharmaceuticals Ltd. and supplied globally by Saif Pharma, is a high-dose anthracycline chemotherapy injection designed for advanced cancer treatment. Containing the potent active ingredient Doxorubicin, this cytotoxic agent is clinically proven for breast cancer, leukemia, lymphoma, sarcomas, and other solid tumors. By intercalating DNA and inhibiting topoisomerase II, Doxotor 50 mg disrupts cancer cell replication and induces apoptosis, offering targeted efficacy in monotherapy and combination regimens.

Key Indications & Therapeutic Benefits

Doxotor 50 mg is indicated for:

• Breast Cancer: Locally advanced or metastatic disease.
• Leukemias: Acute lymphoblastic leukemia (ALL) and acute myeloblastic leukemia (AML).
• Pediatric Cancers: Wilms’ tumor, neuroblastoma, and soft tissue/bone sarcomas.
• Lymphomas: Hodgkin’s and non-Hodgkin’s lymphoma.
• Solid Tumors: Ovarian, gastric, bladder, thyroid, and bronchogenic carcinomas.

Mechanism of Action:

• DNA Intercalation: Binds to DNA/RNA, blocking replication and transcription.
• Topoisomerase II Inhibition: Forms DNA-cleavable complexes, triggering apoptosis.
• Free Radical Generation: Generates hydroxyl radicals, contributing to cytotoxicity (and cardiotoxicity).

Pharmacology & Pharmacokinetics

• Chemical Class: Anthracycline antibiotic (derived from Streptomyces peucetius).
• Metabolism: Hepatic, producing active metabolites (e.g., doxorubicinol).
• Excretion: Primarily biliary (40–50%) with a half-life of 20–48 hours.
• Protein Binding: 75%, ensuring prolonged tissue distribution.

Recommended Dosage & Administration

Standard Regimens (IV infusion over 3–5 minutes):

• Single Agent: 60–75 mg/m² every 21 days (dose adjusted using 50 mg vials as needed).
• Combination Therapy: 40–60 mg/m² every 21–28 days (e.g., with cyclophosphamide or fluorouracil).

Dose Adjustments:

• Hepatic Impairment:
  • Bilirubin 1.2–3.0 mg/dL: Reduce dose by 50%.
  • Bilirubin 3.1–5.0 mg/dL: Reduce dose by 75%.
• Myelosuppression: Delay treatment until ANC ≥1000/mm³ and platelets ≥100,000/mm³.

Administration Guidelines:

1. Infusion: Administer via a freely running IV with 0.9% NaCl or 5% dextrose.
2. Avoid Extravasation: Use large veins and monitor for infiltration (risk of tissue necrosis).
3. Incompatibilities: Do not mix with heparin, fluorouracil, or alkaline solutions.

Contraindications & Safety Warnings

• Hypersensitivity: Avoid in patients allergic to anthracyclines.
• Neutropenia: Baseline neutrophil count must be ≥1500/mm³.
• Cardiotoxicity: Cumulative lifetime dose limit of 550 mg/m² to prevent heart failure.

Critical Warnings:

1. Cardiotoxicity: Monitor LVEF via echocardiogram before and during treatment.
2. Myelosuppression: Severe neutropenia (80% incidence), anemia (60%).
3. Extravasation Risk: Tissue necrosis if leakage occurs; terminate infusion immediately if suspected.

Common Side Effects

• Hematologic: Neutropenia (80%), anemia (60%), thrombocytopenia (15%).
• Gastrointestinal: Nausea/vomiting (70%), mucositis (40%), diarrhea (20%).
• Dermatologic: Alopecia (90%), radiation recall dermatitis (10%).
• Cardiac: Asymptomatic LVEF decline (10%), arrhythmias (5%).
• Other: Red-orange urine discoloration (harmless).

Storage & Handling

• Storage: Store at 2–25°C; protect from light. Freezing does not affect stability.
• Reconstitution: Use sterile diluents (0.9% NaCl or 5% dextrose). Discard unused portions.

Why Choose Doxotor 50 mg from Saif Pharma?

Saif Pharma, a leading global distributor of oncology medications, partners with Eskayef Pharmaceuticals Ltd.—a WHO-GMP-certified manufacturer under Bangladesh’s Transcom Group—to deliver high-quality, affordable chemotherapy drugs to 60+ countries, including the USA, Canada, UAE, and India. Eskayef’s 31-year legacy of producing world-class medicines ensures Doxotor 50 mg meets international safety and efficacy standards. 

Clinical Advantages of Doxorubicin

• Broad Spectrum: Effective against hematologic malignancies and solid tumors.
• Synergy in Regimens: Enhances outcomes in combination with taxanes, cyclophosphamide, and platinum agents.
• Proven Survival Benefit: Cornerstone of adjuvant breast cancer and lymphoma therapies.

Patient Management Tips

• Premedication: Administer antiemetics (e.g., ondansetron) to manage nausea.
• Cardiac Monitoring: Baseline and periodic echocardiograms.
• Hydration: Encourage fluids to mitigate renal toxicity.

Overdose Management

Overdose may exacerbate myelosuppression or cardiotoxicity. No specific antidote exists; manage with G-CSF for neutropenia and cardiac support.

Conclusion

Doxotor 50 mg (Doxorubicin) Injection by Eskayef Pharmaceuticals is a critical component of modern oncology, offering potent antitumor activity with vigilant toxicity management. For authentic, cost-effective access, trust Saif Pharma—your global partner in cancer care.